Drug Index


Mechanism :

It is an antiviral agent and inhibits viral DNA and RNA synthesis. It is used for in the treatment of chronic hepatitis due to HCV C and RSV infections in high-risk patients.

Indication :

  • Chronic Hepatitis C
  • Respiratory Syncytial Virus (inhalation)
  • Hemorrhagic fever with renal syndrome (HFRS) secondary to Hantavirus infection
  • Lassa fever prophylaxis
  • Adenovirus infection
  • SSPE

Contraindications :

Hypersensitivity, Pregnancy, Male partners of pregnant women, Significant or unstable cardiac disease, Hemoglobinopathies, Autoimmune hepatitis, Hepatic impairment, Child-Pugh Class B or C, CrCl <50.

Dosing :

Oral for Hepatitis C along with combination therapy:
15 mg/kg/day in divided doses PO. Max: 800 mg/day.
Inhalation for RSV:
6 g nebulised over 12-18 hours/day for 3-7 days.
Adenovirus infection:
33 mg/kg IV loading dose, followed by 16 mg/kg IV every 6 hours for 4 days, then 8 mg/kg IV every 8 hours for 3 to 6 days (total 7 to 10 day course). Other reports use a 35 mg/kg IV loading dose then 25 mg/kg IV every 8 hours or 15 mg/kg IV every 6 hours.
Intrathecal ribavirin to maintain CSF concentrations between 50 to 200 mcg/ml. The initial dose is 1 mg/kg diluted with saline and injected as 1 to 2 ml via the Ommaya reservoir 1 to 3 times daily. Max: 3 mg/kg/dose.

Adverse Effect :

Hemolytic anemia, eczema, suicidal ideation, pulmonary embolism, aplastic anemia, peptic ulcer, thrombotic thrombocytopenic purpura (TTP), pancreatitis, pulmonary hypertension, pneumothorax, cyanosis, pulmonary edema, apnea, bronchospasm, red cell aplasia, bradycardia, leukopenia, thrombocytopenia, hypothyroidism, constipation, fever, fatigue, headache, asthenia, myalgia, alopecia, arthralgia.

Interaction :

Abacavir: Ribavirin may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy.
Zalcitabine: Ribavirin may increase the hepatotoxicity of zalcitabine. May cause lactic acidosis. Monitor for lactic acidosis during concomitant therapy.
Zidovudine: Increased risk or severity of anemia. Consider alternate therapy or monitor more closely for anemia.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function. Avoid oral.
10-20Dose as in normal renal function. Avoid oral.
<10Dose as in normal renal function. Avoid oral.

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in GFR<10 mL/min
HDNot dialysed. Dose as in GFR<10 mL/min
HDF/High fluxUnknown dialysability. Dose as in GFR<10 mL/min
CAV/VVHDUnknown dialysability. Dose as in GFR=10–20 mL/min

Hepatic Dose :

No dose adjustment recommended. Safety and efficacy have not been established in patients with decompensated hepatic disease.
02/19/2024 23:37:49 Ribavirin
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0